Human-Centered Design in AI-Driven Clinical Decision Making

By Sumona Bose

February 6, 2024

Introduction

Artificial intelligence (AI) technologies have revolutionized the healthcare industry, particularly in the realm of clinical decision support systems (CDSS). These AI-empowered systems provide patient-specific recommendations to improve clinical work. However, alongside technical advancements, it is crucial to consider the human, social, and contextual factors that impact the successful implementation and user adoption of AI-CDSS. Human-centered design plays a pivotal role in ensuring the effectiveness and acceptance of these systems. Human centered design in AI has been an important research avenue.

The Role of AI in Clinical Decision Making

AI-empowered CDSS has shown great promise in enhancing patient evaluation and work efficiency. By analyzing vast amounts of data, AI algorithms can identify patterns and provide clinicians with valuable insights for making informed decisions. This technology has the potential to revolutionize healthcare by improving diagnostic accuracy, treatment planning, and patient outcomes.

Understanding User Needs and Experiences

To gain a comprehensive understanding of AI-CDSS, a systematic review was conducted, analyzing 20 relevant articles published between 2011 and 2022. The studies assessed various aspects of AI-CDSS, including effectiveness, user needs, user experience, and other dimensions.

The effectiveness of AI-CDSS was demonstrated through improved patient evaluation and work efficiency. Clinicians reported that AI recommendations helped them make more accurate diagnoses and develop personalized treatment plans. This technology has the potential to significantly enhance clinical decision-making processes.

User needs and experiences were also explored in the reviewed studies. Clinicians expressed the importance of having access to relevant and timely information, as well as the need for user-friendly interfaces. Additionally, factors such as satisfaction, trust, usability, workload, and understandability were found to influence the acceptance and adoption of AI-CDSS.

www.frontiersin.org
Figure 1: System features and examples.

Challenges in Implementing AI-CDSS

Despite the promising nature of AI-CDSS, the systematic review identified several challenges in implementing these systems. Technical limitations, such as algorithmic biases and data quality issues, can hinder the accuracy and reliability of AI recommendations. Workflow misalignment, attitudinal barriers, and informational barriers were also identified as challenges that impact the effective use of AI-CDSS in clinical settings.

Conclusion

The integration of artificial intelligence in clinical decision-making processes holds great potential for improving patient outcomes and work efficiency. However, the successful implementation of AI-empowered clinical decision support systems requires careful consideration of human-centered design principles and addressing the challenges identified in this study. By prioritizing user needs and experiences, healthcare professionals can harness the full benefits of AI technology in healthcare.

Reference url

Recent Posts

NICE Kidney Cancer Guideline: Enhancing Biopsy Use to Minimize Unnecessary Surgery

By João L. Carapinha

September 18, 2025

The NICE kidney cancer guideline represents a major shift in how renal cell carcinoma is diagnosed and managed in the UK. How does this guideline change the standard of kidney cancer care? By emphasizing more accurate diagnosis—especially the targeted use of kidney biopsies—it aims to avoid unnec...
CAPVAXIVE Pneumococcal Vaccine Delivers Strong Immune Response in At-Risk Youth

By HEOR Staff Writer

September 17, 2025

What makes the CAPVAXIVE pneumococcal vaccine significant for children and adolescents at higher risk for pneumococcal disease? The CAPVAXIVE pneumococcal vaccine (21-valent conjugate vaccine) demonstrated robust immune responses and broad serotype coverage in Merck’s Phase 3 STRIDE-13 trial. ...
Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascular Perks

By HEOR Staff Writer

September 16, 2025

Novo Nordisk’s oral semaglutide (Rybelsus®) has received a significant label update from the European Medicines Agency (EMA). It is now the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved in the EU for type 2 diabetes with proven cardiovascular benefits. This deci...